Urinary melatonin levels and postmenopausal breast cancer risk in the nurses' health study cohort

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 1, 2009, Pages 74-79

  Schernhammer, Eva S ^a,b,c,d   Hankinson, Susan E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; MELATONIN; MELATONIN RECEPTOR;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HORMONE URINE LEVEL; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; URINALYSIS;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MELATONIN; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 58349115423     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0637     Document Type: Article

References (45)

1. Baskett JJ, Cockrem JF, Antunovich TA. Sulphatoxymelatonin excretion in older people: relationship to plasma melatonin and renal function. J Pineal Res 1998;24:58-61.
2. Graham C, Cook MR, Kavet R, Sastre A, Smith DK. Prediction of nocturnal plasma melatonin from morning urinary measures. J Pineal Res 1998;24:230-8.
3. Vijayalaxmi, Thomas CR, Jr., Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002;20: 2575-601.
4. Blask DE, Brainard GC, Dauchy RT, et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005;65:11174-84.
5. Stevens RG. Electric power use and breast cancer: a hypothesis. Am J Epidemiol 1987;125:556-61.
6. Gonzalez A, Martinez-Campa C, Mediavilla MD, et al. Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. Oncol Rep 2007;17:947-53.
7. Ram PT, Dai J, Yuan L, et al. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett 2002;179:141-50.
8. Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM. MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol 2002; 192:147-56.
9. Molis TM, Spriggs LL, Hill SM. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 1994;8:1681-90.
10. Rato AG, Pedrero JG, Martinez MA, del Rio B, Lazo PS, Ramos S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 1999;13:857-68.
11. Lawson NO, Wee BE, Blask DE, Castles CG, Spriggs LL, Hill SM. Melatonin decreases estrogen receptor expression in the medial preoptic area of inbred (LSH/SsLak) golden hamsters. Biol Reprod 1992;47:1082-90.
12. Straif K, Baan R, Grosse Y, et al.; Group., O, b. o. t. W. I. A. f. R. o. C. M. W. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol 2007;8:1065-6.
13. Stevens RG, Blask DE, Brainard GC, et al. Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases. Environ Health Perspect 2007;115:1357-62.
14. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst 2005;97:1084-7.
15. Travis RC, Allen DS, Fentiman IS, Key TJ. Melatonin and breast cancer: a prospective study. J Natl Cancer Inst 2004;96:475-82.
16. Schernhammer ES, Berrino F, Krogh V, et al. Urinary 6-Sulfatoxymelatonin Levels and Risk of Breast Cancer in Postmenopausal Women. J Natl Cancer Inst 2008;100:898-905.
17. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Hennekens CH, Speizer FE. Dietary fat and the risk of breast cancer. N Engl J Med 1987;316:22-8.
18. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-9.
19. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-9.
20. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
21. Adebamowo CA, Cho E, Sampson L, et al. Dietary flavonols and flavonol-rich foods intake and the risk of breast cancer. Int J Cancer 2005;114:628-33.
22. Rosner B. Percentage points for a generalized ESD many-outlier procedure. Technometrics 1983;25:165-72.
23. Willett WC, Browne ML, Bain C, et al. Relative weight and risk of breast cancer among premenopausal women. Am J Epidemiol 1985; 122:731-40.
24. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44: 1049-60.
25. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8:551-61.
26. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. J Natl Cancer Inst 2001;93:1563-8.
27. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 2001;93:1557-62.
28. Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiology 2001;12:74-7.
29. Tamarkin L, Danforth D, Lichter A, et al. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 1982;216:1003-5.
30. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the U S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect 2005;113:192-200.
31. Bartsch C, Bartsch H, Bellmann O, Lippert TH. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer 1991;67:1681-4.
32. Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellmann O, Gupta D. Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors. Cancer 1989;64:426-33.
33. Bartsch C, Bartsch H, Jain AK, Laumas KR, Wetterberg L. Urinary melatonin levels in human breast cancer patients. J Neural Transm 1981;52:281-94.
34. Bartsch C, Bartsch H, Karenovics A, Franz H, Peiker G, Mecke D. Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumor-size. J Pineal Res 1997;23: 53-8.
35. Danforth DNJ, Tamarkin L, Mulvihill JJ, Bagley CS, Lippman ME. Plasma melatonin and the hormone-dependency of human breast cancer. J Clin Oncol 1985;3:941-8.
36. Falkson G, Falkson HC, Steyn ME, Rapoport BL, Meyer BJ. Plasma melatonin in patients with breast cancer. Oncology 1990; 47:401-5.
37. Lissoni P, Bastone A, Sala R, et al. The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels. Eur J Cancer Clin Oncol 1987;23:949-57.
38. Lissoni P, Crispino S, Barni S, et al. Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer. Oncology 1990;47:275-7.
39. Skene DJ, Bojkowski CJ, Currie JE, Wright J, Boulter PS, Arendt J. 6-sulphatoxymelatonin production in breast cancer patients. J Pineal Res 1990;8:269-76.
40. Kajdaniuk D, Marek B, Kos-Kudla B, et al. Does the negative correlation found in breast cancer patients between plasma melatonin and insulin-like growth factor-I concentrations imply the existence of an additional mechanism of oncostatic melatonin influence involved in defense? Med Sci Monit 2002;8: CR457-61.
41. Carlson LE, Campbell TS, Garland SN, Grossman P. Associations among salivary cortisol, melatonin, catecholamines, sleep quality and stress in women with breast cancer and healthy controls. J Behav Med 2007;30:45-58.
42. Hrushesky WJ, Blask DE. Re: Melatonin and breast cancer: a prospective study. J Natl Cancer Inst 2004;96:888-9.
43. Fonseca R, Hartmann LC, Petersen IA, Donohue JH, Crotty TB, Gisvold JJ. Ductal carcinoma in situ of the breast. Ann Intern Med 1997;127:1013-22.
44. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 1982;50:1309-14.
45. Schernhammer ES, Rosner B, Willett WC, Laden F, Colditz GA, Hankinson SE. Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev 2004;13:936-43.